Potential MS Treatments on the Horizon BTK Inhibitors That’s a really huge field of research right now,” she said. “However, the challenge lies in finding drugs that can actually prevent disability once it starts progressing insidiously. “There's a lot of companies working to improve the tolerability, for example, of these medications and put new agents on the market in these families,” she said.ĭoctors currently prescribe DMTs to prevent flares, halt new scars on MRI scans, and slow or stave off disability progression, said Waubant. There are different classes or families of DMTs, some of which have several options within them, whereas other classes may have limited options, noted Dr. DMTs Have Transformed MS Treatment but There Is Still Much Work to Be DoneĮmmanuelle Waubant, MD, PhD, a professor of neurology and MS researcher at University of California in San Francisco, began her presentation on MS disease-modifying therapies (DMTs) by highlighting the “remarkable transformation” of the treatment landscape, with more than 25 medications now available to treat disease progression. On June 3, 2023, the organization gathered top MS researchers from around the United States for its MS Forum and Expo in Los Angeles, to discuss the latest advances in treatments. To date, the organization has raised over $50 million for multiple sclerosis research.
It also happens to be the year that Nancy Davis founded Race to Erase MS, an organization dedicated to funding cutting-edge, aggressive, and promising research in pursuit of a cure.
In 1993, interferon beta-1b made history as the first drug to ever be approved for multiple sclerosis (MS).
0 kommentar(er)
